Clinical Trial DRUG CSLCT-AML-11-73
- A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse
- Principal Investigator
- Jessica Altman
- Status: COMPLETED
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG CSLCT-AML-11-73
- The main purpose of the study is to find out the safety and effectiveness of repeat doses of CSL362 at increasing dose levels.
- Acute myeloid leukemia(AML) is often not cured because of rare cells called “leukemic stem cells” that are not killed by chemotherapy. It may take only few of these cells need to survive for the leukemia to grow back. It is believed that these leukemic stem cells' destruction is key cure AML. Lab studies show that CSL362 targets these rare cells, stops their growth,and kills them.CSL362 is an investigational (drug not approved by the U.S. Food & Drug Administration[FDA]). This study will determine how safe and well tolerated CSL362 is in participants who are at risk for an early relapse (cancer returns)of AML.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older.
- Participants must have completed treatment for AML and achieved complete remission (the disappearance of all signs of cancer).
- Participants must have a life expectancy of 5 months or greater.
- Description of Treatment
- Participants will receive CSL362 intravenously (through a vein) once every 2 weeks for a period of 10 weeks. Participants will receive 6 doses unless their study doctor finds it in their best interest to stop.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Jessica Altman
- A Phase I, Open, Cohort Dose Escalation Trial with BI 836858 in Patients with Refractory or Relapsed Acute Myeloid Leukemia
- A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation
- A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Hematologic Malignancies with an IDH1 and/or IDH2 Mutation
last updated: 30-Aug-16 12:03 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.